Abstract：
As millions of people worldwide recover from COVID-19, a substantial proportion continue to have persistent symptoms, pulmonary function abnormalities, and radiological findings suggestive of post-COVID interstitial lung disease (ILD). To date, there is limited scientific evidence on the management of post-COVID ILD, necessitating a consensus-based approach.
A panel of experts in pulmonology and thoracic radiology was constituted. Key questions regarding the management of post-COVID ILD were identified. A search was performed on PubMed and EMBASE and updated till 1 March 2022. The relevant literature regarding the epidemiology, pathophysiology, diagnosis and treatment of post-COVID ILD was summarized. Subsequently, suggestions regarding the management of these patients were framed, and a consensus was obtained using the Delphi approach. Those suggestions which were approved by over 80% of the panelists were accepted. The final document was approved by all panel members.
Dedicated facilities should be established for the care of patients with post-COVID ILD. Symptom screening, pulmonary function testing, and thoracic imaging have a role in the diagnosis. The pharmacologic and non-pharmacologic options for the management of post-COVID ILD are discussed. Further research into the pathophysiology and management of post-COVID ILD will improve our understanding of this condition.
A panel of experts in pulmonology and thoracic radiology was constituted. Key questions regarding the management of post-COVID ILD were identified. A search was performed on PubMed and EMBASE and updated till 1 March 2022. The relevant literature regarding the epidemiology, pathophysiology, diagnosis and treatment of post-COVID ILD was summarized. Subsequently, suggestions regarding the management of these patients were framed, and a consensus was obtained using the Delphi approach. Those suggestions which were approved by over 80% of the panelists were accepted. The final document was approved by all panel members.
Dedicated facilities should be established for the care of patients with post-COVID ILD. Symptom screening, pulmonary function testing, and thoracic imaging have a role in the diagnosis. The pharmacologic and non-pharmacologic options for the management of post-COVID ILD are discussed. Further research into the pathophysiology and management of post-COVID ILD will improve our understanding of this condition.
摘要：
随着全球数百万人从COVID-19中恢复过来，很大一部分人继续出现持续症状，肺功能异常，和放射学检查结果提示COVID后间质性肺病（ILD）。迄今为止,关于后COVIDILD管理的科学证据有限，必须采取基于共识的方法。
组成了肺科和胸部放射学专家小组。确定了有关COVID后ILD管理的关键问题。在PubMed和EMBASE上进行了搜索，并更新至2022年3月1日。有关流行病学的相关文献，病理生理学,总结了COVID后ILD的诊断和治疗。随后，关于这些患者的管理的建议是框架，并使用德尔菲法获得了共识。被80%以上的小组成员批准的那些建议被接受。最后文件得到了所有小组成员的批准。
应建立专门的设施来护理COVID后ILD患者。症状筛查,肺功能测试,胸部影像学在诊断中也有作用。讨论了COVID后ILD管理的药理学和非药理学选择。对COVID后ILD的病理生理学和管理的进一步研究将提高我们对这种情况的理解。
组成了肺科和胸部放射学专家小组。确定了有关COVID后ILD管理的关键问题。在PubMed和EMBASE上进行了搜索，并更新至2022年3月1日。有关流行病学的相关文献，病理生理学,总结了COVID后ILD的诊断和治疗。随后，关于这些患者的管理的建议是框架，并使用德尔菲法获得了共识。被80%以上的小组成员批准的那些建议被接受。最后文件得到了所有小组成员的批准。
应建立专门的设施来护理COVID后ILD患者。症状筛查,肺功能测试,胸部影像学在诊断中也有作用。讨论了COVID后ILD管理的药理学和非药理学选择。对COVID后ILD的病理生理学和管理的进一步研究将提高我们对这种情况的理解。
